Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks

References

• Aditya NP, Macedo AS, Doktorovova S, et al. (2014). Development and evaluation of lipid nanocarriers for quercetin delivery: a comparative study of solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and lipid nanoemulsions (LNE). Food Sci Technol 59:115–21.
   Web of Science ®Google Scholar
• Ahmed IS, El-Hosary R, Shalaby S, et al. (2016). PD-PK evaluation of freeze-dried atorvastatin calcium-loaded poly-epsilon-caprolactone nanoparticles. Int J Pharm 504:70–9.
   PubMed Web of Science ®Google Scholar
• Anwar M, Warsi MH, Mallick N, et al. (2011). Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats. Eur J Pharm Sci 44:241–9.
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Li Y, et al. (2004). Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res 21:2226–33.
   PubMed Web of Science ®Google Scholar
• Cavalli R, Bargoni A, Podio V, et al. (2003). Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 92:1085–94.
   PubMed Web of Science ®Google Scholar
• Charman WN. (2000). Lipids, lipophilic drugs, and oral drug delivery – some emerging concepts. J Pharm Sci 89:967–78.
   PubMed Web of Science ®Google Scholar
• Chen CC, Tsai TH, Huang ZR, et al. (2010). Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 74:474–82.
   PubMed Web of Science ®Google Scholar
• Chen TY, Pan BS. (2007). Ex vivo inhibitory effect on tilapia LDL oxidation and hypolipidemia properties of Glycine tomentella root extract. Comp Biochem Physiol A Mol Integr Physiol 148:189–95.
   PubMed Web of Science ®Google Scholar
• Choudhary A, Rana AC, Aggarwal G, et al. (2012). Development and characterization of an atorvastatin solid dispersion formulation using skimmed milk for improved oral bioavailability. Acta Pharmaceutica Sinica B 2:421–8.
   Google Scholar
• Elbahwy IA, Ibrahim HM, Ismael HR, et al. (2017). Enhancing bioavailability and controlling the release of glibenclamide from optimized solid lipid nanoparticles. J Drug Deliv Sci Technol 38:78–89.
   Google Scholar
• Elmowafy M, Samy A, Raslan MA, et al. (2016). Enhancement of bioavailability and pharmacodynamic effects of thymoquinone via nanostructured lipid carrier (NLC) formulation. AAPS PharmSciTech 17:663–72.
   PubMed Web of Science ®Google Scholar
• Guinedi AS, Mortada ND, Mansour S, et al. (2005). Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm 306:71–82.
   PubMed Web of Science ®Google Scholar
• He C, Yin L, Tang C, et al. (2012). Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs. Biomaterials 33:8569–78.
   PubMed Web of Science ®Google Scholar
• Higuchi T. (1963). Mechanism of sustained‐action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 52:1145–9.
   PubMed Web of Science ®Google Scholar
• Hörter D, Dressman JB. (2001). Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 46:75–87.
   PubMed Web of Science ®Google Scholar
• Hussein AK, Ibrahim MA, Amin MA, et al. (2011). Improved in vitro dissolution parameters and in vivo hypolipidemic efficiency of atorvastatin calcium through the formation of hydrophilic inclusion complex with cyclodextrins. Drug Dev Res 72:379--90.
   Web of Science ®Google Scholar
• Hyogo H, Yamagishi S, Maeda S, et al. (2012). Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-alpha-lowering property. Dig Liver Dis 44:492–6.
   PubMedGoogle Scholar
• Jeong W-I, Jeong D-H, Do S-H, et al. (2005). Mild hepatic fibrosis in cholesterol and sodium cholate diet-fed rats. J Vet Med Sci 67:235–42.
   PubMed Web of Science ®Google Scholar
• Jia LJ, Zhang DR, Li ZY, et al. (2010). Preparation and characterization of silybin-loaded nanostructured lipid carriers. Drug Deliv 17:11–18.
   PubMed Web of Science ®Google Scholar
• Joshi M, Patravale V. (2008). Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm 346:124–32.
   PubMed Web of Science ®Google Scholar
• Kim MS, Jin SJ, Kim JS, et al. (2008). Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 69:454–65.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, et al.; Nonalcoholic Steatohepatitis Clinical Research, N. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41:1313–21.
   PubMed Web of Science ®Google Scholar
• Lau YY, Okochi H, Huang Y, et al. (2006). Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 34:1175–81.
   PubMed Web of Science ®Google Scholar
• Levy M, Benita S. (1990). Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model. Int J Pharm 66:29–37.
   Web of Science ®Google Scholar
• Marasini N, Yan YD, Poudel BK, et al. (2012). Development and optimization of self-nanoemulsifying drug delivery system with enhanced bioavailability by Box-Behnken design and desirability function. J Pharm Sci 101:4584–96.
   PubMed Web of Science ®Google Scholar
• Muller RH, Petersen RD, Hommoss A, et al. (2007). Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 59:522–30.
   PubMed Web of Science ®Google Scholar
• Müller RH, Rühl D, Runge SA. (1996). Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int J Pharm 144:115–21.
   Web of Science ®Google Scholar
• O'driscoll CM, Griffin BT. (2008). Biopharmaceutical challenges associated with drugs with low aqueous solubility–the potential impact of lipid-based formulations. Adv Drug Deliv Rev 60:617–24.
   PubMed Web of Science ®Google Scholar
• Porter C. (2001). Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 50:61–80.
   PubMed Web of Science ®Google Scholar
• Ravi PR, Aditya N, Kathuria H, et al. (2014). Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism. Eur J Pharm Biopharm 87:114–24.
   PubMed Web of Science ®Google Scholar
• Sachs-Barrable K, Thamboo A, Lee SD, et al. (2007). Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of Rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 Cells. J Pharm Pharm Sci 10:319–31.
   PubMed Web of Science ®Google Scholar
• Sanad RA, Abdelmalak NS, Elbayoomy TS, et al. (2010). Formulation of a novel oxybenzone-loaded nanostructured lipid carriers (NLCs). AAPS PharmSciTech 11:1684–94.
   PubMed Web of Science ®Google Scholar
• Saupe A, Wissing SA, Lenk A, et al. (2005). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) – structural investigations on two different carrier systems. Biomed Mater Eng 15:393–402.
   PubMed Web of Science ®Google Scholar
• Shah RP, Kumar V, Singh S. (2008). Liquid chromatography/mass spectrometric studies on atorvastatin and its stress degradation products. Rapid Commun Mass Spectrom 22:613–22.
   PubMed Web of Science ®Google Scholar
• Shete H, Patravale V. (2013). Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization. Int J Pharm 454:573–83.
   PubMed Web of Science ®Google Scholar
• Souto EB, Wissing SA, Barbosa CM, et al. (2004). Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 278:71–7.
   PubMed Web of Science ®Google Scholar
• Tiwari R, Pathak K. (2011). Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 415:232–43.
   PubMed Web of Science ®Google Scholar
• Vila L, Rebollo A, Adalsteisson GS, et al. (2011). Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicol Appl Pharmacol 251:32–40.
   PubMed Web of Science ®Google Scholar
• Vila L, Roglans N, Alegret M, et al. (2008). Suppressor of cytokine signaling-3 (SOCS-3) and a deficit of serine/threonine (Ser/Thr) phosphoproteins involved in leptin transduction mediate the effect of fructose on rat liver lipid metabolism. Hepatology 48:1506–16.
   PubMed Web of Science ®Google Scholar
• Wang J, Xia Q. (2014). Alpha-lipoic acid-loaded nanostructured lipid carrier: sustained release and biocompatibility to HaCaT cells in vitro. Drug Deliv 21:328–41.
   PubMed Web of Science ®Google Scholar
• Wong PCH, Heng PWS, Chan LW. (2016). Viscosity-temperature relationship of lipid-based excipients amenable for spray congealing: derivation of a rheological parameter with good correlation to particle size. Eur J Lipid Sci Technol 118:1062–73.
   Web of Science ®Google Scholar
• Xu X, Khan MA, Burgess DJ. (2012). A two-stage reverse dialysis in vitro dissolution testing method for passive targeted liposomes. Int J Pharm 426:211–18.
   PubMed Web of Science ®Google Scholar
• Yu Q, Hu X, Ma Y, et al. (2016). Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus. Drug Deliv 23:1469–75.
   PubMed Web of Science ®Google Scholar
• Zhang L, Han L, Sun X, et al. (2012). The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B. Fitoterapia 83:678–89.
   PubMed Web of Science ®Google Scholar
• Zheng S, Hoos L, Cook J, et al. (2008). Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 584:118–24.
   PubMed Web of Science ®Google Scholar
• Zhuang CY, Li N, Wang M, et al. (2010). Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 394:179–85.
   PubMed Web of Science ®Google Scholar